Inclusion of indigenously developed Covaxin in the WHO list will boost global acceptance of the Covid-19 vaccine. : Pre-configured baskets of stocks & ETFs that you can invest in with a single click. Developed by hedge funds, global asset management companies, experienced wealth management firms and portfolio managers. Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas A World Health Organization expert panel is scheduled to review the clinical trial data of Bharat Biotech’s Covid-19 vaccine Covaxin on October 5, according to the committee’s agenda for the meeting.
In this article
No tags related to this article.